Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • PRC2-mediated apoptosis evasion is a therapeutic target of MDS/AML harboring inv(3)/t(3;3) and-7
    Meeting Abstract

    Kunimoto, H.; Miura, A.; Sagisaka, M.; Ito, M.; Honma, D.; Tsutsumi, S.; Sakuma, T.; Ohashi, T.; Teranaka, H.; Ikeda, J.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A pro-inflammatory gene signature characterizes a better risk aged AML patient group in ECOG-ACRIN Cancer Research Group's clinical trial E3999
    Meeting Abstract

    Neelamraju, Y.; Rapaport, F.; Gandara, J. A.; Dunham, N.; Fan, H.; Lee, T.; Prajapati, S.; Sheridan, C.; Wang, L.; Cripe, L. D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Patterns and safety of glucocorticosteroids use following CD19 CAR-T cell therapy for B-cell lymphoma
    Meeting Abstract

    Luttwak, E.; Flynn, J. R.; Devlin, S. M.; Cassanello, G.; Corona, M.; Dahi, P. B.; Luna De Abia, A.; Fein, J.; Giralt, S. A.; Landego, I.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • First fever between lymphodepletion and day 30 after CAR-T cell therapy: Patterns, origins, and implications in lymphoma patients
    Meeting Abstract

    Melica, G.; Luna, A.; Fei, T.; Corona, M.; Dahi, P. B.; Fein, J.; Giralt, S. A.; Raj, S.; Landego, I.; Lin, R. J.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • From widespread to tailored antifungal prophylaxis in lymphoma patients treated with CD19 CAR T- cell therapy: Less is better
    Meeting Abstract

    Melica, G.; Luna De Abia, A.; Corona, M.; Fein, J.; Dahi, P. B.; Giralt, S. A.; Landego, I.; Lin, R. J.; Palomba, M. L.; Parascondola, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
    Meeting Abstract

    Bewersdorf, J. P.; Derkach, A.; Masarova, L.; Pemmaraju, N.; Stein, E. M.; Mauro, M.; Rampal, R. K.; Bose, P.
    Blood (2023)

    Fulltext@MSK | Save
  • A phase 2 study of minimal residual disease (MRD)-adapted front line venetoclax and obinutuzumab in fit patients with chronic lymphocytic leukemia (CLL): Effect of obinutuzumab on tumor lysis syndrome (TLS) risk and safety of outpatient venetoclax dose escalation
    Meeting Abstract

    Roeker, L. E.; Zelenetz, A. D.; Park, J. H.; Derkach, A.; Geyer, M. B.; Islam, P.; Falchi, L.; Palomba, M. L.; Kumar, A.; Salles, G.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A phase 1b multi-center study of the FLT3 inhibitor gilteritinib in combination with the IDH1 inhibitor ivosidenib or the IDH2 inhibitor enasidenib for patients with relapsed or refractory acute myeloid leukemia who have co-occurring FLT3/IDH1 or FLT3/IDH2 mutations
    Meeting Abstract

    Stein, E. M.; Derkach, A.; Melamed, G.; Block, A.; Kim, J.; Georgieva, G.; Thompson, V.; Levine, R. L.; Intlekofer, A. M.; Abdel-Wahab, O.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Venetoclax in combination with pediatric-inspired chemotherapy in adults with newly diagnosed acute lymphoblastic leukemia: Results of a phase I trial
    Meeting Abstract

    Valtis, Y. K.; Geyer, M. B.; Torres, M.; Grogan, M.; Shukla, M.; Stein, E. M.; Park, J. H.
    Blood (2023)

    Fulltext@MSK | Save
  • Evaluation of the impact of tocilizumab use in recipients of CAR T cells for non-Hodgkin lymphoma
    Meeting Abstract

    Cassanello, G.; Luttwak, E.; Devlin, S. M.; Luna De Abia, A.; Corona, M.; Landego, I.; Parascondola, A.; Saldia, A.; Tomas, A. A.; Dahi, P. B.; more...
    Blood (2023)

    Fulltext@MSK | Save